First human test of new HIV pill halted after just 4 people
NCT ID NCT07115368
Summary
This was an early, small study to test the safety and initial effects of a new HIV medication called GS-1219. It involved only 4 people living with HIV who were not on other treatments. The main goals were to see how the drug moves through the body and if it can lower the amount of virus, but the study was stopped early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AXCES Research Group
El Paso, Texas, 79902, United States
-
AXCES Research Group
Salt Lake City, Utah, 84102, United States
-
BLISS Health Inc
Orlando, Florida, 32803, United States
-
Be Well Medical Center
Berkley, Michigan, 48072, United States
-
Central Texas Clinical Research
Austin, Texas, 78705, United States
-
Midland Florida Clinical Research Center
DeLand, Florida, 32720, United States
-
Midway Immunology and Research Center
Ft. Pierce, Florida, 34982, United States
-
Mills Clinical Research
Los Angeles, California, 90069, United States
-
North Texas Infectious Diseases Consultants
Dallas, Texas, 75246, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States
-
Prism Health North Texas
Dallas, Texas, 75208, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
-
Ruane Clinical Research Group
Los Angeles, California, 90036, United States
-
Triple O Research Institute
West Palm Beach, Florida, 33407, United States
-
Washington Health Institute
Washington D.C., District of Columbia, 20017, United States
Conditions
Explore the condition pages connected to this study.